Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed · Phase 3 · Has a placebo group

Conditions studied: Uterine Fibroids, Heavy Menstrual Bleeding

In brief

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Key facts

Study ID
NCT03070951
Run by
ObsEva SA
People needed
511
Starts
2017-05-23
Expected to finish
2020-10-04
Last updated by the study team
2021-03-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.